Q-omics provides the consensus-scored HOXA11-AS profile across patient tissues and cancer cell-line models. HOXA11-AS expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, HOXA11-AS is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, HOXA11-AS RNA expression shows 14,982 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, KIRC, and TGCT as cancer lineages where HOXA11-AS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HOXA11-AS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HOXA11-AS survival associations across molecular data types. HOXA11-AS RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HOXA11-AS RNA expression–survival associations across cancer types. High HOXA11-AS expression shows unfavorable associations in KIRP, ACC, MESO, KIRC and LGG, but favorable associations in COAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for HOXA11-AS RNA expression.
This table summarizes HOXA11-AS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for HOXA11-AS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HOXA11-AS shows lower tumor expression in KIRC and BLCA and higher tumor expression in HNSC, LUAD, STAD and LUSC. The KIRC box plot shows higher HOXA11-AS RNA expression in normal versus tumor tissue (log2 FC = −1.108, t-test p < 0.001).
This table shows molecular features associated with HOXA11-AS in patient tissues and cancer cell lines. In patient samples, HOXA11-AS shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
